Ticker > Company >

Aurobindo Pharma share price

Aurobindo Pharma Ltd.

NSE: AUROPHARMA BSE: 524804 SECTOR: Pharmaceuticals & Drugs  252k   1k   288

1,124.75
+1.85 (0.16%)
BSE: 27 Jun 04:01 PM

Price Summary

Today's High

₹ 1,138.45

Today's Low

₹ 1,119.50

52 Week High

₹ 1,592.55

52 Week Low

₹ 994.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

65,325.66 Cr.

Enterprise Value

68,049.16 Cr.

No. of Shares

58.08 Cr.

P/E

37.4

P/B

3.18

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  353.55

CASH

94.34 Cr.

DEBT

2,817.84 Cr.

Promoter Holding

51.82 %

EPS (TTM)

₹  30.08

Sales Growth

25.88%

ROE

10.06 %

ROCE

11.56%

Profit Growth

52.97 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Aurobindo Pharma Ltd.

Molnaflu Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR Cold-EEZE MidNite Geritol Vivarin Enoxaklot Doripure Aurosakro Lecarpon Levospec Moxirobe Ibadenz Viatuff Fery-tasty Renor Rinoban Benzer Autidine Diclor Kenalac Ketohist Zmox Plus Actralika Nevirex Nelvex Indivex Celdol Ad 500 Zmox Pryde Diceta Otacut Tripcut Helicut Freeoxy Flumox Aurox Zolcer Kit Clarion Oxyfree Auronim Sf Auronim Md

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.88%
3 Year-12.38%
5 Year-2.78%

Profit Growth

1 Year59.25%
3 Year-14.38%
5 Year5.02%

ROE%

1 Year10.06%
3 Year8.65%
5 Year12.56%

ROCE %

1 Year11.56%
3 Year9.46%
5 Year13.48%

Debt/Equity

0.14

Price to Cash Flow

38.10

Interest Cover Ratio

14.16

CFO/PAT (5 Yr. Avg.)

1.30

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 51.82 16.92
Dec 2024 51.82 17.83
Sep 2024 51.82 20.39
Jun 2024 51.80 20.88
Mar 2024 51.83 20.86
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 1,324.73 Cr.
  • Company has a healthy Interest coverage ratio of 14.16.
  • Company’s PEG ratio is 0.71.
  • The company has a good cash flow management; CFO/PAT stands at 1.30.

 Limitations

  • The company has shown a poor profit growth of -15.17% for the Past 3 years.
  • The company has shown a poor revenue growth of -12.38% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 2,894.03 2,460.09 2,824.59 2,916.63 2,731.99
Total Expenditure 2,119.24 1,961.16 2,103.71 2,203.48 2,135.48
Operating Profit 774.79 498.93 720.88 713.15 596.51
Other Income 122.97 65.32 122.66 54.26 113.98
Interest 53.07 51.13 51.63 66.19 61.09
Depreciation 64.81 66.88 68.16 68.28 93.88
Exceptional Items 0 0 0 0 0
Profit Before Tax 779.88 446.24 723.75 632.94 555.52
Tax 201.21 117.20 186.22 160.89 147.35
Profit After Tax 578.67 329.04 537.53 472.05 408.17
Adjusted EPS (Rs) 9.88 5.62 9.26 8.13 7.03

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 13,370.77 15,823.68 11,287.14 8,457 10,645.64
Total Expenditure 10,672.90 11,703.85 9,831.60 6,952.09 8,421.60
Operating Profit 2,697.87 4,119.83 1,455.54 1,504.91 2,224.04
Other Income 388.79 589.86 688.85 443.92 616.06
Interest 243.28 28.68 16.94 74.58 182.60
Depreciation 473.33 488 415.26 243.26 254.58
Exceptional Items 0 0 -74.71 0 0
Profit Before Tax 2,370.05 4,193.01 1,637.48 1,630.99 2,402.92
Tax 493.17 1,080.10 182.77 388.82 502.82
Net Profit 1,876.88 3,112.91 1,454.71 1,227.11 1,954.14
Adjusted EPS (Rs.) 32.03 53.13 24.83 21.20 32.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 58.59 58.59 58.59 58.59 58.59
Total Reserves 12,993.91 15,866.02 17,058.75 17,975.44 19,664.23
Borrowings 0 0 0 0 0
Other N/C liabilities 138.86 1,412.13 4,566.44 3,138.49 3,399.83
Current liabilities 6,372.25 6,756.58 4,180.97 6,993.24 5,746.81
Total Liabilities 19,563.61 24,093.32 25,864.75 28,165.76 28,869.46
Assets
Net Block 4,417.80 4,472.07 3,585.83 3,687.50 2,419.13
Capital WIP 814.85 719.02 225.15 239.09 132.68
Intangible WIP 0 15.87 0 0 0
Investments 2,527.39 4,880.89 6,584.35 8,105.36 13,393.43
Loans & Advances 444.90 1,610.41 5,605.43 5,800.45 5,012.10
Other N/C Assets 70.37 59.05 28.88 53.78 170.92
Current Assets 11,288.30 12,336.01 9,835.11 10,279.58 7,741.20
Total Assets 19,563.61 24,093.32 25,864.75 28,165.76 28,869.46
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2,370.05 4,193.01 1,637.48 1,611.23 2,475.41
Adjustment 414.20 53.15 -30.65 175.20 69.61
Changes in Assets & Liabilities -204.18 -624.78 2,811.95 330.37 -228.04
Tax Paid -378.69 -626.85 -692.07 -300.63 -602.18
Operating Cash Flow 2,201.38 2,994.53 3,726.71 1,816.17 1,714.80
Investing Cash Flow -948.08 -2,650.24 -1,614.54 -3,229.65 -151.58
Financing Cash Flow -1,254.65 -28.06 -2,447.54 1,719.48 -1,837.03
Net Cash Flow -1.35 316.23 -335.37 306 -273.81

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 51.83 51.80 51.82 51.82 51.82
axis clinicals limited 0.11 0.11 0.11 0.11 0.11
axis clinicals limited, t... 2.85 2.85 2.85 2.85 2.85
k rajeswari - - 0.31 - 0.31
k spoorthi - - - - 1.19
kambam nityananda reddy - - - 4.37 4.37
kirthi reddy kambam 3.49 3.46 3.45 3.45 3.45
m sivakumaran 2.47 2.47 2.47 2.47 2.47
m sumanth kumar reddy 0.27 0.27 0.27 0.27 0.27
prasada reddy kambham 0.05 0.05 0.05 0.05 0.05
rpr sons advisors private... 33.51 33.51 33.50 33.50 33.50
suneela rani penaka 0.02 0.02 0.02 0.02 0.02
trident chemphar limited 0.13 0.13 0.13 0.13 0.13
venkata ramprasad reddy p... 3.07 3.07 3.07 3.07 3.07
k spoorthi - - 1.19 1.19 -
rajeswari kambam - - - 0.31 -
k nityananda reddy 4.33 4.33 4.37 - -
kambam spoorthi 1.19 1.19 - - -
rajeshwari kambam 0.31 0.31 - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 48.17 48.20 48.18 48.18 48.18
hdfc mutual fund - hdfc s... - - - - 4.33
icici prudential nifty ph... - - - - 2.95
investor education and pr... - 0.14 0.15 - 0.15
life insurance corporatio... 3.38 2.78 2.08 2.08 2.45
mirae asset large cap fun... 2.84 - - - 2.52
nps trust- a/c icici prud... - - 1.57 1.92 2.20
quant mutual fund-quant e... - - - - 3.99
hdfc mutual fund-hdfc arb... - 4.34 - 4.33 -
icici prudential s&p bse ... - - - 2.94 -
investor education and pr... 0.14 - - 0.15 -
mirae asset elss tax save... - - - 2.43 -
quant mutual fund - quant... - - - 3.60 -
hdfc large and mid cap fu... - - 4.42 - -
icici prudential manufact... - - 3.17 - -
mirae asset nifty midcap ... - - 2.34 - -
quant mutual fund - quant... - 3.27 3.60 - -
icici prudential regular ... - 4.20 - - -
mirae asset nifty 200 alp... - 2.69 - - -
hdfc mutual fund 3.78 - - - -
icici prudential mutual f... 3.60 - - - -
quant mutual fund 2.54 - - - -

Annual Reports

Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
Credit INDIA RATINGS & RESEARCH
Credit FITCH
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Markets Ltd.
Research Motilal Oswal
Research Prabhudas Lilladhar
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q4FY22
Concall Q4FY22
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY23
Concall Q2FY21
Concall Q1FY24
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY25
Presentation Q2FY25
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21

Company News

Aurobindo Pharma Stock Price Analysis and Quick Research Report. Is Aurobindo Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time. Aurobindo Pharma stock price today is Rs 1121.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Aurobindo Pharma cash from the operating activity was Rs 1,714.80 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.14 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was 52.97 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 20.89 % which is a good sign for profitability.
     
  • ROE: Aurobindo Pharma have a average ROE of 10.06 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Aurobindo Pharma is Rs 1121. One can use valuation calculators of ticker to know if Aurobindo Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Aurobindo Pharma
X